Cytokine Overproduction, T-Cell Activation, and Defective T-Regulatory Functions Promote Nephritis in Systemic Lupus Erythematosus by Tucci, Marco et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 457146, 6 pages
doi:10.1155/2010/457146
Review Article
CytokineOverproduction,T-Cell Activation, and
Defective T-Regulatory Functions Promote Nephritis
in SystemicLupus Erythematosus
Marco Tucci, Stefania Stucci, SabinoStrippoli, andFrancesco Silvestris
DIMO, Department of Internal Medicine and Clinical Oncology, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
Correspondence should be addressed to Marco Tucci, m.tucci@dimo.uniba.it
Received 5 February 2010; Accepted 15 March 2010
Academic Editor: Brian Poole
Copyright © 2010 Marco Tucci et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Lupus nephritis (LN) occurs in more than one-third of patients with systemic lupus erythematosus. Its pathogenesis is mostly
attributabletotheglomerulardepositionofimmunecomplexesandoverproductionofThelper-(Th-)1cytokines.Inthiscontext,
the high glomerular expression of IL-12 and IL-18 exerts a major pathogenetic role. These cytokines are locally produced by both
macrophagesanddendriticcells(DCs)whichattractotherinﬂammatorycells leadingtomaintenanceofthekidneyinﬂammation.
However, other populations including T-cells and B-cells are integral for the development and worsening of renal damage. T-cells
include many pathogenetic subsets, and the activation of Th-17 in keeping with defective T-regulatory (Treg) cell function regards
as further event contributing to the glomerular damage. These populations also activate B-cells to produce nephritogenic auto-
antibodies.Thus,LNincludesacomplexpathogeneticmechanismthatinvolvesdiﬀerentplayersandtheevaluationoftheiractivity
may provide an eﬀective tool for monitoring the onset of the disease.
1.Introduction
Lupus nephritis (LN) is a major clinical manifestation
of systemic lupus erythematosus that occurs in 15% of
patients at diagnosis and in approximately 40% during the
course of the disease. Renal biopsy is the gold standard for
the diagnosis and follow-up, whereas the measurement of
proteinuria identiﬁes patients with overt renal failure, but
fails to detect early silent disease. Thus, a better deﬁnition
of the pathogenetic mechanisms leading to LN is required to
identify eﬀective markers of renal inﬂammation.
LN is generally attributed to an intriguing interplay bet-
ween renal parenchymal cells and inﬂammatory cells recr-
uitedinconsequenceofthedepositionand/orinsituproduc-
tion of immune complexes (ICs) [1]. ICs increase the pro-
duction of cytokines, chemokines, and adhesion molecules
which allow the progressive inﬁltration of macrophages,
dendritic cells (DCs) and T-cells resulting in chronic renal
failure [2]. Moreover, cytokines and chemokines secreted by
cells inﬁltrating glomeruli further promote the migration
of other inﬂammatory cells that are attracted toward the
inﬂammatory sites in response to a concentration gradient
[3, 4].
Notwithstanding SLE is considered a T helper- (Th-) 2
driven disease [5–7], experimental models of LN proved the
primary role of Th1 cytokines for its development and sever-
ity, since large amounts of both interleukin- (IL-) 12 and IL-
18 have been found within glomeruli of humans as well as
in murine models of glomerulonephritis [8–11]. In parallel,
high amounts of Th2 cytokines as IL-6 and IL-10 were found
inseraofSLEpatientswithactivedisease,althoughtheywere
not clearly associated with renal damage [12].
Macrophages and DCs are major producers of cytokines
within glomeruli and their interaction with resident T-
cells ampliﬁes the renal inﬂammation. In this context, the
impaired T-cell activation as altered function of DCs has
been demonstrated in SLE, whereas DCs activate na¨ ıve T-
cells and regulate the cytokine production, and the T-cell
polarization [13]. It has been recently described as a defect
of circulating DCs in parallel with their increased migration
toward the kidney due to attractive stimuli promoted by
glomerular IL-18, IL-1, and chemerin [14]. Thus, while2 Journal of Biomedicine and Biotechnology
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Figure 1: Representation of pathogenetic mechanisms of lupus nephritis. LN is a disease that includes several mediators of glomerular
inﬂammation. In this context, T-cell subsets, through the production of nephritogenic cytokines or by cooperating with B-cells,
macrophages, and dendritic cells promote the activation of the glomerular immune response.
glomerular IL-18 is nephritogenic since it recruits IL-
18R+ DCs, these cells locally produce IL-12, interferon-
(IFN-) γ and CXCR4 thus amplifying the immune-mediated
glomerular damage. In addition, expansion of Th-17-
producing cells and defective number and function of T-
regulatory (Treg) cells have been demonstrated in LN [15].
Here, we review recent data on the key role of both Th1
and Th2 cytokines in LN and focus the defect of Th17 and
Tregs in the modulation of inﬂammatory signals leading to
the worsening of SLE renal function.
2.Pathogenetic Relevance of T-Cell Function in
LupusNephritis
Derangement of T-cell function has been demonstrated in
SLE in parallel to abnormal cytokine production associated
to loss of immune tolerance, increased antigenic load, and
defective B-cell suppression. A large number of studies
suggested that SLE is a Th2-driven disease [5–7]. However,
elevation of both Th1 and Th2 cytokines occurs in both
humans and mice suggesting that SLE is a complex disease
driven by diﬀerent lymphocyte subsets [8] with high het-
erogeneity of clinical manifestations and organ involvement
(Figure 1).
2.1. T-Cell Activation. T-cells play a crucial role in the
pathogenesis of experimental and human LN, since they
activate B-cell functions including the production of nephri-
togenic antibodies and the modulation of T helper immune
response. Moreover, T-cells inﬁltrate the glomeruli and pro-
mote either direct cytotoxicity or recruit other inﬂammatory
cells as macrophages and DCs [16]. Many studies suggested
an imbalance in T-cell subsets, and reported an increase of
CD4+ c e l l sw i t hr e s p e c tt oC D 8 +, altered Th1/Th2 cytokine
production, and raise of the circulating CD4−/CD8− subset.
In this context, murine α/β and γ/δ CD4−/CD8− cells induce
B-cells to produce both anti-dsDNA and antichromatin
antibodies and thus have been considered the major inducer
of renal failure in experimental SLE [17–19]. Moreover,
disruption of T-cell signals in experimental LN by depletion
of α/β T-cells or by blocking the CD40/CD40 ligand cascade,
delays the inﬂammatory state of LN and improves the
proteinuria with reduced glomerular accumulation of both
inﬂammatory cells and nephritogenic antibody [20]. In
addition, γ/δ T-cells and CD16/CD56 natural killer cells
cooperate in lupus, since MLR/lpr mice lacking these pop-
ulations develop severe nephritis associated with polyclonal
CD4+ T-cell expansion [21]. Thus, it is conceivable that
CD4+ T-cells exert a negative regulatory function.Journal of Biomedicine and Biotechnology 3
A parallel defective function of T-cell suppressor has
been demonstrated. In fact, peripheral CD4+/CD25+ Tregs
are reduced in patients with active LN, and expansion of
this population through tolerogenic peptides strongly delays
nephritis as well as the production of auto-antibodies by B-
cells [22]. Since T-cell subsets produce diﬀerent cytokines
in response to inﬂammatory stimuli, their measurement is
considered an eﬀective tool for explaining the pathogenetic
mechanisms of LN.
2.2. Cytokine Imbalance in Lupus Nephritis. Most of infor-
mation concerning the pathogenetic role of cytokines in LN
derives from murine models relevant for investigating the
disease mechanisms under deﬁned experimental conditions.
In particular, knock-out mice for either cytokines and/or
cytokine-receptors emphasized the role of IFN-γ and IL-
12 [23], since treatment with relative neutralizing antibod-
ies prevents renal disease in NZB/W mice, while IFN-γ
receptor−/− MRL/lpr are protected from glomerulonephritis
and show defective anti-dsDNA production [24]. Moreover,
these mice strains show high IL-12 production, whereas
those defective for the cytokine are protected from LN
through inhibition of both IFN-γ and IL-18 production.
Other studies deﬁned the IL-18 functions in MRL/lpr
mice and demonstrated that its glomerular accumulation
occurs in patients with proliferative glomerulonephritis and
correlates with the inﬁltration of IL-18R+ DCs [8, 10, 25].
However, the majority of therapeutic approaches in
humans with biologic or genetic modulation of cytokine
production provided inconsistent results. This was at least
in part attributed to the identiﬁcation that IL-23 and IL-
27 [26], additional members of the IL-6/IL-12 family may
amplify the Th1 immune response through expansion of
the CD4+ Th17+ cells [27]. Th17 cells develop under the
inﬂuence of IL-6, TGF-β, and IL-23, and produce IL-17 [28].
Recently, the urinary expression of Th17 related genes has
been demonstrated in patients with LN and thus further
studiesmightberelevantforexplainingitsroletohumanLN.
We have recently provided evidence that production of
Th1 over Th2 cytokines occurs in active LN, since a defect
of both IL-6 and IL-10 counterbalances elevations of IFN-γ,
IL-12, and IL-18 in both sera and urine in the majority of
patients.
IL-6 is a pleyotropic cytokine produced by a large
variety of cells that primes the diﬀerentiation of B-cells into
antibody-producing cells as well as the diﬀerentiation of
T-cells to eﬀector cells and the activation of macrophages.
IL-6 promotes the proliferation of renal mesangial cells in
mice and several studies report IL-6 as a critical mediator
of tissue damage for its ability to stimulate the production
of nephritogenic antibodies in humans [29]. Moreover,
it has been reported that urinary excretion of IL-6 is
elevated in patients with active LN, whereas it declines
during the treatment [30]. These studies, however, have not
demonstrated a deﬁnite relationship between serum and/or
urinary IL-6 overproduction in renal disease. As shown
in Figure 2(a), we demonstrated in patients with SLE a
remarkable increment of serum IL-6 with respect to normal
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Figure 2: Th1/Th2 cytokine proﬁle in SLE. (a) Patients with LN
(n = 69) produced large amounts of both IL-12 and IL-18, both
in sera (black column) and urine (gray column). By contrast, those
with diﬀerent organ damages (n = 181) excluding LN, showed the
highest production of IL-6 and IL-10. (b) IL-6 was overproduced in
patients with high levels of anti-dsDNA antibodies independently
from the presence of LN. Other cytokines were poorly associated
with nephritogenic antibody production.
subjects (P<. 05). However, both serum and urinary IL-
6 levels derived from LN patients were not associated with
the presence of renal injury, although they were increased
in patients with high levels of anti-dsDNA and antinuclear
antibodies (Figure 2(b)). This suggests the potential role of4 Journal of Biomedicine and Biotechnology
IL-6 for the stimulation of auto-antibody production by B-
cells, rather than acting as direct mediator of glomerular
inﬂammation.
IL-10 has also been extensively studied. It is a key
factor in regulating auto-antibody-secreting B-cell activity
and promotes B-cell diﬀerentiation [31]. Elevated levels of
serum IL-10 occur in SLE, although the treatment with
anti-IL-10 monoclonal antibody failed to restore the disease
activity in the majority of patients [32]. Moreover, IL-10
e l e v a t i o no c c u r si nd i ﬀerent clinical conditions associated to
SLE and a speciﬁc association with organ damage has not
been deﬁnitively elucidated. Our data are in agreement with
these results for the high levels of serum IL-10 (P<. 05)
in both patients with and without LN, whereas elevations
of urinary IL-10 were revealed in those with minimal
glomerular lesions. Thus, we concluded that overexpression
of IL-10 in SLE may reﬂect an intrinsic defect of the cytokine
homeostasis. However, it remains unclear whether elevations
of IL-10 are a cause or, rather, an eﬀect of this dysregulation.
Measurement of Th1 cytokines (Figure 2(a))p r o v i d e d
diﬀerent results, since both IL-12 and IL-18 were strongly
overexpressed in LN (410 ± 90 and 618 ± 105pg/ml), cor-
related with IFN-γ overproduction (P<. 05), and increased
in their concentrations within the kidney of patients with
proliferative glomerulonephritis. Parallel analyses revealed a
large number of IL-18R+ DCs in glomeruli inﬁltrated by
IL-18+ cells, thus suggesting that the cytokine also exerts a
potent chemoattraction of inﬂammatory cells expressing the
functional receptor. Additional studies also demonstrated a
peculiar association between both serum and urinary IL-12
with serum IFN-γ (P<. 05) in LN. In this context, presence
of urinary neopterin as a bioactive marker of serum IFN-
γ production further supported the Th1 predominance in
kidney inﬂammation.
3.Interleukin-17ProducingT-Cells
IL-17 is a 17-kDa transmembrane protein that includes
six members and ﬁve receptors mostly produced by acti-
vated T-cells. Although the downstream signals activated
by IL17R remains to be elucidated, it has been recently
shown that its stimulation activates both the nuclear factor
kB and MAP kinase cascades [27]. IL-17 exerts a potent
proinﬂammatory activity in parallel with functional recruit-
ment of macrophages and neutrophils within inﬂamed
tissues through the overproduction of IL-8 and monocyte
chemoattractant protein-1 [33]. This cytokine also allows
the expression of adhesion molecules by T-cells as well as
the production of IL-6 and GM-CSF. Lastly, IL-17 synergizes
with IL-1β, tumor necrosis factor- (TNF-) α and IFN-γ,
and ampliﬁes the Th1 immune response in autoimmune
disorders [34].
IL-17 is mostly produced by CD4+,C D 8 +,C D 4 −/CD8−,
and γ/δ T-cells, and the CD4+ T-cell eﬀector subset,
namely the Th17 cells, has been distinguished from other
T helper populations for the speciﬁc origin, diﬀerentiation,
and cytokine production. Recent studies demonstrated the
involvement of Th17 cell in the pathogenesis of SLE,
since NZB/NZWF1 mice produce relevant amounts of the
cytokine while IL-17 producing T-cells largely inﬁltrate the
nephritic kidneys of these mice [35]. By contrast, treatment
with anti-CD3 monoclonal antibodies delayed the renal
damage with concurrent defect of IL-17 production in both
serum and glomeruli [36]. Parallel studies in lupus-prone
mice described that presence of IL-23 as necessary for
the development of a pathogenic Th17 functional immune
response. In fact, IL-23 increases the IL-17 production by
memory T-cells, thus suggesting a novel T helper functional
axis formed by IL23/IL-17 interaction, almost similar to the
IL-12/IFN-γ system. Moreover, it has been demonstrated
that the majority of IL-17 producing T-cells arises from
the CD3+/CD4−/CD8− subset, that is the typical population
revealed in nephritic glomeruli from MRL/lpr mice. There-
fore, this cell population is considered an active mediator of
renal cytotoxicity [37, 38]. It is conceivable that IL-17+ T-
cells amplify the inﬂammatory signals activated by other Th1
cytokines. In this context, its inhibition by targeted therapies
should represent a novel option for the treatment of patients
with overt renal disease.
4.Regulatory T-Cells andDendriticCells in
LupusNephritis
Regulatory T-cells (Tregs) are a heterogeneous population
of CD4+/CD8+/CD25+ cells diﬀerentiated in two subsets
in relation to the expression of Foxp3 transcription factor.
TheFoxp3− populationincludesbothIL-10-producingTregs
and Th3 cells that express the transforming growth factor-
(TGF-) β. By contrast, Foxp3+ Tregs play a protective role
in autoimmunity since they regulate the eﬃciency of the
immune response. Notwithstanding Foxp3 is not necessary
for the diﬀerentiation of Tregs, its expression prevents T-
cells to diﬀerentiate into Th17 proinﬂammatory eﬀector T-
cells[39].Thisisconsistentwiththeacceleratedautoimmune
manifestations observed in mice depleted of Foxp3+ Tregs or
in humans characterized by a genetic mutation of the Foxp3
gene [40]. Similarly, natural Tregs exert a protective eﬀect
in lupus-prone mice, since depletion of CD4+/CD25+ cells
in NZB/NZWF1 accelerates the onset of LN, whereas their
transferintoCD4/CD25knock-outmicedelaystheglomeru-
lonephritis development. Moreover, high IL-6 production
may interfere with Treg function and promote their switch
toward Th17-producing cells [41]. In addition, stimulation
and activation of DCs in nephritic glomeruli are promoted
by interferons while limiting both expansion and protective
functions of Tregs in SLE. Thus, although Tregs play an
apparent primary role for the homeostasis of the immune
system in SLE, the mechanisms leading to their depletion
are unclear [42]. It has been suggested that defective
number of peripheral Tregs in lupus promotes T- and B-cell
hyperactivity while recent studies have attributed this defect
to dysfunctional DC activation. For this reason, the restoring
of the balance between immunogenic and tolerogenic DCs
may represent a mechanism for the inhibition of IL-17
cytotoxicity and the correction of Treg defect during the
active phases of LN.
Defective DC function and glomerular accumulation
of these cells in LN are regarded as a consequenceJournal of Biomedicine and Biotechnology 5
of their increased recruitment from peripheral blood in
response to chemotactic stimuli [10, 43]. DCs interact
with renal parenchymal cells through the activation of toll-
like-receptors, FC-receptors, c-type lectins, and scavenger
receptor, that, once stimulated by either cell-to-cell contact
or paracrine signals, accelerate the enrollment of NK, T-
cells, and γ/δ lymphocytes in inﬂammatory sites [44].
Furthermore, DCs exhibit the hallmark of well-equipped
antigen-presenting cells in presence of peculiar costimu-
latory molecules and chemokine proﬁle. In this scenario,
presence of DCs within nephritic glomeruli supports their
pathogenic eﬀect. This aspect may thus explain why recent
therapeutic approaches aimed to their functional disabling,
ameliorate nephritis in rodents[45].
5. Conclusions
RecentdatafromexperimentalandhumanLNprovidednew
insights to the role of cytokine interplay in the pathogenesis
of renal damage. In this context, a cutting-edge on the Th1
deregulation has been demonstrated and both IL-12 and IL-
18 exert a major nephritogenic role. However, further studies
are needed to clarify the interplay of other mechanisms
including both Th17 expansion and defective Treg function
within inﬂamed glomeruli. Therefore, development and
progression of renal failure in SLE is an event that involves
multiple players whose regulation by novel-therapeutic
strategies might prevent the progressive worsening of LN.
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